Share on StockTwits

MedAssets (NASDAQ:MDAS) Director Terrence J. Mulligan sold 1,000 shares of the company’s stock on the open market in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $21.97, for a total transaction of $21,970.00. Following the completion of the transaction, the director now directly owns 927 shares of the company’s stock, valued at approximately $20,366. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

MDAS has been the subject of a number of recent research reports. Analysts at Raymond James reiterated an “outperform” rating on shares of MedAssets in a research note on Thursday, July 31st. They now have a $27.50 price target on the stock, up previously from $25.00. Separately, analysts at Citigroup Inc. downgraded shares of MedAssets from a “buy” rating to a “neutral” rating in a research note on Thursday, May 29th. They now have a $26.00 price target on the stock, down previously from $28.00. Finally, analysts at Bank of America downgraded shares of MedAssets from a “buy” rating to a “neutral” rating in a research note on Thursday, May 22nd. They now have a $24.00 price target on the stock, down previously from $25.00. Eleven analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $25.66.

Shares of MedAssets (NASDAQ:MDAS) opened at 21.19 on Monday. MedAssets has a one year low of $19.38 and a one year high of $26.58. The stock’s 50-day moving average is $22.74 and its 200-day moving average is $23.15. The company has a market cap of $1.273 billion and a price-to-earnings ratio of 45.09.

MedAssets (NASDAQ:MDAS) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.30 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.29 by $0.01. The company had revenue of $175.42 million for the quarter, compared to the consensus estimate of $175.70 million. During the same quarter last year, the company posted $0.30 earnings per share. MedAssets’s revenue was up 2.7% compared to the same quarter last year. Analysts expect that MedAssets will post $1.34 EPS for the current fiscal year.

MedAssets, Inc (NASDAQ:MDAS) provides technology-enabled products and services.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.